Reimbursement listing for Lilly’s ‘Retevmo cap(selpercatinib),’ the first RET-targeted anticancer therapy in Korea, is gaining speed after successfully setting reimbursement standards.

As the drug is eligible for expedited listing in Korea as a treatment used for life-threatening conditions, its time to reimbursement listing is expected to be further shortened.

The Health Insurance Review and Assessment Service announced that it had held the 9th Cancer Disease Deliberation Committee meeting and made the decision on the 2nd.

At the meeting, CDDC set new reimbursement standards for Retevmo Cap as a treatment for ‘advanced or metastatic RET-mutated medullary thyroid can